title: Altered regulation of insulin-like growth factor binding protein-1 in patients with polycystic ovary syndrome.
abstract: OBJECTIVE
  Insulin-like growth factor (IGF-I) action is influenced by circulating as well as tissue levels of its binding proteins. Because serum IGF binding protein-1 (IGFBP-1) levels have been found to be decreased in patients with polycystic ovary syndrome (PCOS), we tested the hypothesis that regulation of IGFBP-1 secretion may be different in patients with PCOS compared with normal women.
  
  
  METHODS
  We studied 15 normal ovulatory women and 15 women with PCOS of similar age (21 +/- 1 and 22 +/- 1 years, respectively). All subjects were studied after an overnight fast between days 5-8 after spontaneous or progestin-induced menses. Perturbations included the administration of insulin intravenously, maintenance of a euglycemic clamp, and, in a subsequent cycle, the administration of a long-acting somatostatin analogue (octreotide, 100 micrograms) given subcutaneously. Blood samples were collected before treatment, every 15 minutes for 6 hours after insulin, and every 30 minutes for 3 hours after octreotide administration. Serum levels of IGF-I, IGFBP-1, IGFBP-3, and insulin were measured by specific immunoassays.
  
  
  RESULTS
  Compared with the controls, patients with PCOS had significantly higher insulin levels, similar IGF-I and IGFBP-3 levels, and significantly lower IGFBP-1. Insulin did not change serum IGF-I levels in either group, although a significant decrease in IGFBP-1 levels occurred in normal women but not in patients with PCOS. Octreotide treatment also did not change serum IGF-I levels in either group, but serum insulin levels decreased significantly and IGFBP-1 levels increased significantly in both groups; this response was significantly greater in controls.
  
  
  CONCLUSIONS
  Our data are compatible with the notion that regulation of IGFBP-1 is altered in women with PCOS and that several factors may be involved.
authors.affiliation: Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, USA.
authors.forename: E
authors.initials: E
authors.lastname: Carmina
authors.forename: F Z
authors.initials: FZ
authors.lastname: Stanczyk
authors.forename: R S
authors.initials: RS
authors.lastname: Morris
authors.forename: P D
authors.initials: PD
authors.lastname: Lee
authors.forename: G
authors.initials: G
authors.lastname: Savjani
authors.forename: R A
authors.initials: RA
authors.lastname: Lobo
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood* / Q000494:pharmacology; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood*; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000378:metabolism; D015282:Octreotide / Q000494:pharmacology; D011085:Polycystic Ovary Syndrome / Q000097:blood*; D012016:Reference Values
chemical_list: D007328:Insulin; D018970:Insulin-Like Growth Factor Binding Protein 1; D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D015282:Octreotide